Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Biochem Pharmacol. 2021 Nov 18;195:114844. doi: 10.1016/j.bcp.2021.114844

Figure 3. HIV-1 latency reversal induced by epigenetic modifiers alone or in combination with Ingenol-3,20-dibenzoate ex vivo.

Figure 3.

Treatment of rCD4 cells isolated from HIV-1 positive aviremic individuals with Ingenol-3,20-dibenzoate significantly increased viral latency reactivation compared to media alone. The positive control αCD3/αCD28 resulted in viral reactivation in all donors. All nine epigenetic modifiers alone or in combination with Ingenol3,20-dibenzoate did not increase reactivation significantly compared to Ingenol-3,20-dibenzoate treatment alone. *P value <0.05; ** P value <0.01. The dotted line indicates the limit of detection of the assay (50 copies/ug cell associated RNA (caRNA)).